We are the region’s only cancer center dedicated solely to the treatment and research of prostate, kidney, bladder and testicular cancers. Our team of over 30 dedicated professionals have one mission: to provide each patient unsurpassed personalized cancer care accomplished through deep heartfelt compassion, extensive and comprehensible education, the most proficient cancer management, and an unparalleled focus on improving survival and quality of life.
We utilize a unique team approach: Dr. Luke and his Clinical Team, Research Coordinators, Treatment Nurses, Pharmacy, Scheduling and Financial staff work simultaneously during a patient’s visit to ensure delivery of the most accurate, personalized, efficient and expert care.
Learn MoreDr. Luke's research team has access to potentially life-prolonging treatments years before they are available to the public. With our access to a growing pipeline of new drugs on clinical trials, UCC has the most available treatment options for urologic cancers compared to all other major centers.
Learn MoreWe understand the financial burdens cancer may cause a patient and their family. We have highly trained and compassionate staff when it comes helping you choose the most appropriate insurance plans and obtaining assistance to minimize your out- of-pocket costs.
Learn MoreDr. Luke takes the time to thoughtfully and thoroughly explain your diagnosis and treatment options. He will not pressure you into any one treatment option; rather, he allows you to make the choice that is best for you. His staff is friendly and professional; they understand that your time is valuable. Dr. Luke and staff helped make an unpleasant situation seem much less scary.
Experts working together for your best outcome.
Cancer research is the only process available to discover and utilize new treatments for cancer patients. The Urology Center & GU Research Network is recognized by thought leaders, patients and pharmaceutical companies as a global leader in research.
Learn MoreEndocyte, Inc. (Nasdaq:ECYT) announced the enrollment of the first patient in its global phase 3 VISION trial of 177Lu-PSMA-617 in prostate cancer by Dr. Luke Nordquist at Urology Cancer Center in Omaha, NE, a member of Precision Cancer Research.
There is growing awareness of the problems and pitfalls with Pharmacy Benefit Managers (PBMs)
in the United States health care system. Contracted by insurance carriers to negotiate on their
behalf with pharmaceutical companies, these ‘middle men’ corporations have quietly become an
unavoidable part of our nation’s health care system.
